Roivant Sciences Stock Performance
| ROIV Stock | USD 22.53 0.20 0.88% |
On a scale of 0 to 100, Roivant Sciences holds a performance score of 9. The company holds a Beta of 0.42, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Roivant Sciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Roivant Sciences is expected to be smaller as well. Please check Roivant Sciences' maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Roivant Sciences' historical price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Roivant Sciences are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward indicators, Roivant Sciences showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.88) | Five Day Return (2.13) | Year To Date Return 2.74 | Ten Year Return 116.63 | All Time Return 116.63 |
1 | Urogen Pharma Reports Q3 Loss, Misses Revenue Estimates | 11/06/2025 |
2 | Disposition of 318282 shares by Venker Eric of Roivant Sciences at 15.85 subject to Rule 16b-3 | 11/14/2025 |
3 | Disposition of 175000 shares by Qvt Financial Lp of Roivant Sciences at 20.24 subject to Rule 16b-3 | 11/19/2025 |
4 | Acquisition by Momtazee James C of 14524 shares of Roivant Sciences subject to Rule 16b-3 | 11/21/2025 |
5 | Disposition of 4672724 shares by Vivek Ramaswamy of Roivant Sciences at 12.68 subject to Rule 16b-3 | 12/12/2025 |
6 | Disposition of 2129 shares by Richard Pulik of Roivant Sciences at 22.41 subject to Rule 16b-3 | 12/19/2025 |
7 | Disposition of 200000 shares by Venker Eric of Roivant Sciences at 22.45 subject to Rule 16b-3 | 12/23/2025 |
8 | Disposition of 748358 shares by Sukhatme Mayukh of Roivant Sciences at 12.68 subject to Rule 16b-3 | 12/29/2025 |
9 | Disposition of 2449877 shares by Sukhatme Mayukh of Roivant Sciences at 12.68 subject to Rule 16b-3 | 12/31/2025 |
10 | Disposition of 189538 shares by Qvt Financial Lp of Roivant Sciences at 23.17 subject to Rule 16b-3 | 01/05/2026 |
11 | What Roivant Sciences s Accelerated Brepocitinib Push Means For Shareholders | 01/08/2026 |
12 | Discipline and Rules-Based Execution in ROIV Response - Stock Traders Daily | 01/13/2026 |
13 | Disposition of tradable shares by Epperly Melissa B, of Roivant Sciences at 22.98 subject to Rule 16b-3 | 01/20/2026 |
14 | Sun Pharma Eyes Organon In What Could Be India Pharmas Biggest Cross-Border Deal Report | 01/22/2026 |
| Begin Period Cash Flow | 6.6 B | |
| Total Cashflows From Investing Activities | -1.8 B |
Roivant Sciences Relative Risk vs. Return Landscape
If you would invest 1,958 in Roivant Sciences on October 30, 2025 and sell it today you would earn a total of 295.00 from holding Roivant Sciences or generate 15.07% return on investment over 90 days. Roivant Sciences is currently generating 0.2544% in daily expected returns and assumes 2.0371% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Roivant, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Roivant Sciences Target Price Odds to finish over Current Price
The tendency of Roivant Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 22.53 | 90 days | 22.53 | about 16.22 |
Based on a normal probability distribution, the odds of Roivant Sciences to move above the current price in 90 days from now is about 16.22 (This Roivant Sciences probability density function shows the probability of Roivant Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Roivant Sciences has a beta of 0.42 indicating as returns on the market go up, Roivant Sciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Roivant Sciences will be expected to be much smaller as well. Additionally Roivant Sciences has an alpha of 0.3263, implying that it can generate a 0.33 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Roivant Sciences Price Density |
| Price |
Predictive Modules for Roivant Sciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Roivant Sciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Roivant Sciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Roivant Sciences is not an exception. The market had few large corrections towards the Roivant Sciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Roivant Sciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Roivant Sciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.33 | |
β | Beta against Dow Jones | 0.42 | |
σ | Overall volatility | 1.37 | |
Ir | Information ratio | 0.14 |
Roivant Sciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Roivant Sciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Roivant Sciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 29.05 M. Net Loss for the year was (356.73 M) with loss before overhead, payroll, taxes, and interest of (581.72 M). | |
| Roivant Sciences currently holds about 1.94 B in cash with (839.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Over 75.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Sun Pharma Eyes Organon In What Could Be India Pharmas Biggest Cross-Border Deal Report |
Roivant Sciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Roivant Stock often depends not only on the future outlook of the current and potential Roivant Sciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Roivant Sciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 725.4 M | |
| Cash And Short Term Investments | 4.9 B |
Roivant Sciences Fundamentals Growth
Roivant Stock prices reflect investors' perceptions of the future prospects and financial health of Roivant Sciences, and Roivant Sciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Roivant Stock performance.
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.12 | ||||
| Operating Margin | (185.95) % | ||||
| Current Valuation | 11.52 B | ||||
| Shares Outstanding | 695.49 M | ||||
| Price To Book | 3.62 X | ||||
| Price To Sales | 777.63 X | ||||
| Revenue | 29.05 M | ||||
| Gross Profit | (581.72 M) | ||||
| EBITDA | (1.1 B) | ||||
| Net Income | (356.73 M) | ||||
| Cash And Equivalents | 1.94 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 100.17 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 6.20 X | ||||
| Book Value Per Share | 6.33 X | ||||
| Cash Flow From Operations | (839.45 M) | ||||
| Earnings Per Share | (0.99) X | ||||
| Market Capitalization | 15.81 B | ||||
| Total Asset | 5.44 B | ||||
| Retained Earnings | 116.06 M | ||||
| Working Capital | 4.85 B | ||||
About Roivant Sciences Performance
Evaluating Roivant Sciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Roivant Sciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Roivant Sciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 7.2 K | 7.6 K | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.04) | (0.04) |
Things to note about Roivant Sciences performance evaluation
Checking the ongoing alerts about Roivant Sciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Roivant Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 29.05 M. Net Loss for the year was (356.73 M) with loss before overhead, payroll, taxes, and interest of (581.72 M). | |
| Roivant Sciences currently holds about 1.94 B in cash with (839.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Over 75.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Sun Pharma Eyes Organon In What Could Be India Pharmas Biggest Cross-Border Deal Report |
- Analyzing Roivant Sciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Roivant Sciences' stock is overvalued or undervalued compared to its peers.
- Examining Roivant Sciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Roivant Sciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Roivant Sciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Roivant Sciences' stock. These opinions can provide insight into Roivant Sciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.